Syndax Pharmaceuticals, Inc.
SNDX
Jodie situation report
Syndax Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
- SNDX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if SNDX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind SNDX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ABBVAbbVie Inc.partnerApr 30, 2026 ▾
“Included in cost of product sales are royalties owed to AbbVie on Revuforj sales as part of the Vitae License Agreement.”
INCYIncyte CorporationpartnerApr 30, 2026 ▾
“We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab.”
Depended on by
INCYIncyte CorporationpartnerApr 28, 2026 ▾
“In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
SNDX is currently a Early Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.